<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02343133</url>
  </required_header>
  <id_info>
    <org_study_id>2014-003</org_study_id>
    <secondary_id>#HHSO100201100037C</secondary_id>
    <nct_id>NCT02343133</nct_id>
  </id_info>
  <brief_title>Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome</brief_title>
  <official_title>A Phase 2 Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HemaMax™ (rHuIL-12) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neumedicines Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Neumedicines Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether HemaMax is safe and well tolerated to
      support efficacy under FDA's Animal Rule to reduce the morbidity and mortality associated
      with the hematopoietic syndrome of acute radiation syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2 single dose, randomized, double-blind, placebo-controlled, multi center
      study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HemaMax™
      (rHuIL-12) in healthy adult male and female subjects considered representative of U.S.
      population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of HemaMax (Number of subjects with adverse events as a measure of safety and tolerability)</measure>
    <time_frame>3 months</time_frame>
    <description>Number of subjects with adverse events as a measure of safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of HemaMax (AUC, Cmax and Tmax)</measure>
    <time_frame>3 months</time_frame>
    <description>PK parameters such as AUC, Cmax and Tmax as measures of pharmacokinetic exposure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of HemaMax (IFN-g and CXCL-10 induction as a measure of pharmacodynamic response)</measure>
    <time_frame>3 months</time_frame>
    <description>IFN-g and CXCL-10 induction as a measure of pharmacodynamic response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of HemaMax (Anti-drug antibodies as a measure of immunogenicity)</measure>
    <time_frame>3 months</time_frame>
    <description>Anti-drug antibodies as a measure of immunogenicity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Acute Radiation Syndrome</condition>
  <arm_group>
    <arm_group_label>HemaMax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous dose of HemaMax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single subcutaneous dose of Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HemaMax</intervention_name>
    <description>Recombinant human interleukin-12 [rHuIL-12]</description>
    <arm_group_label>HemaMax</arm_group_label>
    <other_name>IL-12</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male and Female healthy subjects who have signed the informed consent form must meet all of
        the following criteria

          -  ≥18 to ≤75 years of age

          -  Body mass index (BMI) ≥ 18 and ≤ 35 kg/m2

          -  Normal ECG, vital signs and laboratory test results

          -  Use of effective birth control method and abstinence from sex

          -  Negative pregnancy test and drug screen

        Exclusion Criteria:

        Subjects with any of the following characteristics will be considered ineligible:

          -  History of clinically significant renal, hepatic pulmonary, cardiovascular,
             cerebrovascular, gastrointestinal, metabolic, hematological, endocrine, urological,
             immunological, neurologic or psychiatric disorders or connective tissue disease

          -  Positive for human immunodeficiency virus (HIV), Hepatitis B, or surface antigen
             (HBsAg) or Hepatitis C antibody, tuberculosis (TB)

          -  Drug or alcohol addiction

          -  History of clinically significant allergy of any kind

          -  Prior use of IL-12 or HemaMax

          -  Use of any approved or investigational biologic agents or vaccinations of any kind in
             last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Siebers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ehoonline.org/content/3/1/11</url>
    <description>Single Low-dose rHuIL-12 Safely Triggers Multilineage Hematopoietic and Immune-mediated Effects.</description>
  </link>
  <reference>
    <citation>Gokhale MS, Vainstein V, Tom J, Thomas S, Lawrence CE, Gluzman-Poltorak Z, Siebers N, Basile LA. Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects. Exp Hematol Oncol. 2014 Apr 11;3(1):11. doi: 10.1186/2162-3619-3-11.</citation>
    <PMID>24725395</PMID>
  </reference>
  <reference>
    <citation>Gluzman-Poltorak Z, Vainstein V, Basile LA. Recombinant interleukin-12, but not granulocyte-colony stimulating factor, improves survival in lethally irradiated nonhuman primates in the absence of supportive care: evidence for the development of a frontline radiation medical countermeasure. Am J Hematol. 2014 Sep;89(9):868-73. doi: 10.1002/ajh.23770. Epub 2014 Jun 19.</citation>
    <PMID>24852354</PMID>
  </reference>
  <reference>
    <citation>Gluzman-Poltorak Z, Vainstein V, Basile LA. Association of Hematological Nadirs and Survival in a Nonhuman Primate Model of Hematopoietic Syndrome of Acute Radiation Syndrome. Radiat Res. 2015 Aug;184(2):226-30. Epub 2015 Jul 24.</citation>
    <PMID>26207689</PMID>
  </reference>
  <reference>
    <citation>Gluzman-Poltorak Z, Mendonca SR, Vainstein V, Kha H, Basile LA. Randomized comparison of single dose of recombinant human IL-12 versus placebo for restoration of hematopoiesis and improved survival in rhesus monkeys exposed to lethal radiation. J Hematol Oncol. 2014 Apr 6;7:31. doi: 10.1186/1756-8722-7-31.</citation>
    <PMID>24708888</PMID>
  </reference>
  <reference>
    <citation>Basile LA, Ellefson D, Gluzman-Poltorak Z, Junes-Gill K, Mar V, Mendonca S, Miller JD, Tom J, Trinh A, Gallaher TK. HemaMax™, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates. PLoS One. 2012;7(2):e30434. doi: 10.1371/journal.pone.0030434. Epub 2012 Feb 24.</citation>
    <PMID>22383962</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2015</study_first_submitted>
  <study_first_submitted_qc>January 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2015</study_first_posted>
  <last_update_submitted>August 2, 2016</last_update_submitted>
  <last_update_submitted_qc>August 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiation countermeasure</keyword>
  <keyword>radiomitigation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Radiation Injuries</mesh_term>
    <mesh_term>Acute Radiation Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

